CIPO trademark

MIDACORE

RegisteredCIPOWord markClass 1Class 5Class 40Class 42

"MIDACORE" is a word mark owned by Midatech Limited, filed at the CIPO on February 20, 2018. It is registered and covers classes 1, 5, 40 and 42.

View Midatech Limited portfolioGet this data via the API
Official CIPO record
MIDACORE
Word mark as filed with the CIPO
Status
Registered
Since March 19, 2020
Filed
February 20, 2018
Registered
March 19, 2020
Expires
March 19, 2030
Application no.
1883909
Registration no.
TMA1075535
Office
CIPO
Canadian Intellectual Property Office
Mark type
Word mark
4 classes
Ownership

Who owns MIDACORE

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Midatech Limited

United Kingdom

37 trademarks in the portfolioView company

Representative

Borden Ladner Gervais LLP

Borden Ladner Gervais LLP

Goods and services

What the mark covers

The products and services MIDACORE is filed for, grouped by Nice class.

  • Nanoparticles ingredients for use in the manufacture of pharmaceuticals, medicines and cosmetics; nanoparticles for use as carriers for pharmaceuticals, medicines and cosmetics

  • Pharmaceuticals and medicines containing nano-particles for the treatment of the common cold, influenza, rabies, measles, diarrhea, hepatitis, yellow fever, polio, smallpox, AIDS, oncoviruses, and spongiform encephalopathies, metabolic diseases and disorders, namely diabetes, hypoglycemia, anemia, bulimia nervosa, anorexia, obesity, gout, osteoarthritis, and muscular dystrophy, diseases and disorders related to the musculoskeletal system, namely connective tissue diseases, back pain, fractures, sprains, and cartilage injuries, genitourinary diseases and disorders, namely urological diseases, infertility, sexually transmitted diseases, and inflammatory pelvic diseases, neurological diseases and disorders, namely Alzheimers, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, dermatological diseases and disorders, namely dermatitis, eczema, psoriasis, skin pigmentation diseases, and sexually transmitted diseases, psychiatric diseases and disorders, namely mood disorders, anxiety, cognitive disorders, schizophrenia, cognitive and bipolar disorders, immune system diseases and disorders, namely autoimmune diseases, and immunologic deficiency syndromes, central nervous system diseases and disorders, namely brain, movement, ocular motility, and spinal cord diseases, endocrine diseases and disorders, namely growth and thyroid disorders, diabetes, osteoporosis, Addison's disease, Cushing's syndrome, Grave's disease, hyperglycemia, hypoglycemia, low testosterone, menopause, and obesity, and hormonal diseases and disorders, namely growth disorders, sexual dysfunction disorders, reproductive disorders, mood disorders, sleep disorders, and metabolic disorders, namely diabetes, hypoglycemia, anemia, bulimia nervosa, anorexia, obesity, gout, osteoarthritis, and muscular dystrophy, hormonal diseases and disorders, namely hormone replacement therapy preparations, pancreas hormone preparations, thyroid and para-thyroid hormone preparations, adrenal hormone preparations, and pituitary hormone preparations, and cardiovascular, cardiopulmonary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, and gastrointestinal related diseases and disorders; human vaccines incorporating nano-particles and veterinary vaccines incorporating nano-particles

  • Custom manufacture of nano-particles; custom manufacture of pharmaceuticals and medicines containing nano-particles; custom manufacture of nano-particle devices

  • Scientific research services in the field of nano-particle technology; pharmaceutical and drug development and discovery services; testing, efficiency and advisory services in the field of design, development and scientific research of nano-particles, pharmaceuticals and nano-medicine; nano-particle laboratory services

History

What has happened so far

Steps recorded by the CIPO, newest first.

  1. Registered
  2. Registration Fee Notice Sent
  3. Registration Pending
  4. Advertised; Vol.66 Issue 3392
  5. Approval Notice Sent
  6. Approved
  7. Examiner's First Report
  8. Search Recorded
  9. Formalized
  10. Created

1 earlier step on the official record.

FAQ

About MIDACORE

Who owns the trademark "MIDACORE"?

The CIPO trademark "MIDACORE" (application 1883909) is owned by Midatech Limited.

What is the status of "MIDACORE"?

Its status at the CIPO is: registered.

When was "MIDACORE" registered?

It was registered on March 19, 2020 and is due to expire on March 19, 2030.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull MIDACORE and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019deb75-1eed-75fa-9489-d8ad7cb1dcff
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019deb75-1eed-75fa-9489-d8ad7cb1dcff",
  "object": "trademark",
  "mark_text": "MIDACORE",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "CA",
  "application_number": "1883909",
  "filing_date": "2018-02-20",
  "nice_classes": [
    1,
    5,
    40,
    42
  ],
  "owners": [
    {
      "name": "Midatech Limited",
      "entity_id": "ent_019ebaf3-9aef-735b-a6dd-65e4baf52602"
    }
  ]
}